Retension Pharmaceuticals, Inc.

RTSN Nasdaq SEC CIK 2002988
Follow Retension Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$5.9M −301% vs same quarter last year
EPS, diluted −$7.33 −300.5% vs same quarter last year
Operating income −$6M −260.8% vs same quarter last year
Net income by quarter
−$656.5K
−$1.2M
−$1.5M
−$3.4M
−$4.1M
−$5.9M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing